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THE SUCCESSFUL isolation and subsequent auto-
.1 transplantation of islets into pancreatectomized pa-
tients has promulgated the possible use of this procedure 
for the treatment of insulin-dependent type I diabetes 
(IDOM).1.2 However, our inability to diagnose and 
promptly treat islet allograft rejection combined with the 
deleterious effects of currently used immunosuppressive 
agents have severely limited the clinical utility of this 
approach. In an attempt to evolve a universally applicable 
strategy for the surgical treatment of 100M, we at the 
Thomas E. Starzl Transplantation Institute have per-
formed, between January 1990 and May 1996. 42 pancreatic 
islet cell transplantations. We report herein, the results of 
our 6-year experience with this procedure in humans and 
discuss some of the approaches that we have evolved that 
may assist in the successful engraftment of allotransplanted 
islets. 
MATERIALS AND METHODS 
Patients 
Between 1990 and 1996. 37 patients received pancreatic islet 
allotransplantation (Table 1). Additionally, during the same pe-
riod. five patients underwent autotransplantation of islets isolated 
from pancrcata retrieved from individuals undergoing total or 
partial fl!section (Table 1. group VIII). In an attempt to induce 
ullnor-specitic tolerance. selected diabetic recipients of kidney and 
liver also receiveu a perioperative infusion of 3 to 5 X 10' 
unmoditied bone marrow (BM) cells/kg bodv weight (Table 1. 
groups IV and V). Furthermore, using the percutaneous portal vein 
approach, delayed (31 to 45 days post-organ transplantation) 
infusion of islets cultured in pyruvate-rich mediumJ was performed 
in some patients (Table 1. groups VI and VII). This latter approach 
was prompted with an objective to optimize graft acceptance in 
patients who were anticipated to be on relatively lower doses of 
immunosuppression (IS) with demonstrable immune modulation. 
For IS. recipients of cluster transplants (Table 1, group I) received 
tacrolimus alone, whereas all the other patients (except recipients 
of autografts) received tacrolimus and steroids. The function of 
transplanted islet cells was monitored by serial postoperative 
determinations of plasma glucose. C-peptide. and glycosylated 
hemoglobin (HbA,J levels. An intravenous glucose tolerance test 
or Sustacal challenge test was also performed at regular intervals 
was to ascertain the ability of transplanted islets to respond to 
stress. In selected cases, oral glucose tolerance tests were also 
performed. 
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Table 1. Patient and Graft Survival and Insulin Freedom in Isolated Pancreatic Islet Cell Recipients 
Patients In) 
Fallaw-Up 
Group Total Alive 1%) Range (Mo) Primary Organ Tx C-Peptlde' Insulin-Free 
11 2 (18) 2-77 Cluster 55 6(55%) 
11 10 (91) 0-74 Kidney 45 a 
III 4 1 (33) 1-69 Liver 33 1 (33%) 
IV 1 1 (100) 34 Liver + BM' 0 a 
v 6 6 (100) 26-37 Kidney + BM' 83 a 
VI 2 2 (100) 2-12 Kidney + BM' 100 a 
VII 2 2 (100) 10-13 Kidney' 100 a 
VIII 5 5 (100) 3-64 Autografts 100 4(80%) 
'Percent of recIpients wno exn,b,ted normal levels of crrculatlnq C-peptlde 30 days post-Islel Tx 
'S,multaneous orqan and 8M Tx, 
:S,multaneous orqan and 8M Tx w,m delaved Islet cell Tx 
"Delayed Islet cell T, 
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TREATMENT OF ISOlJl.TED PANCREATIC ISLETS 
Islet Cell Isolation 
Islets were isolated by a modification ()f the automated method 
detailed elsewhere:' Isolated cells were subsequently purified by 
velocity sedimentation on a discontinuous Euro-Collins-Ficoll 
density gradient using a cell separator (Cobe 2991. Cobe Labora-
tories Inc. Lakewood, Colo). Islet number, purity, and viability 
were determined by dithizone staining and 0.2 to 1.7 x 104 isletSlkg 
body weight were infused into each patient. 
Culture in Pyruvate-Rich Medium 
For patients receiving delayed islet cell allografts, a known concen-
tration (60 to 80 islets/mL) of isolated islets were cultured in 
pyruvate-enriehed (S to 7 mmoI/L) medium supplemented with S 
mmoI/L D-glucose, S% to 10% fetal calf serum and 2S mmoVL 
HEPES (Gibeo, Grand Island, NY). The cells were maintained at 
37"C in 5% CO2 in air until infusion.J Five days prior to and on the 
day of infusion, extensive microbiologic testing was performed to 
ensure the sterility of the infusate. 
RESULTS AND DISCUSSION 
A comprehensive account of the outcome in the first 37 
successive cases has been published previously. 1.2 Although 
only 2 of 11 (18%) cluster transplant recipients are cur-
rently alive and insulin-dependent. it is nevertheless note-
worthy that hyperglycemia was reversed in 6 of 11 (55%) 
patients who maintained an insulin-free existence until 
succumbing to recurrence of malignancy. Interestingly, 
included among them was the longest survivor who was 
insulin-free for 58 months after islet cell transplantation 
(Tx) until her demise which was a consequence of multiple 
system organ failure precipitated by the recurrence of 
primary malignancy.s 
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While four of five (80%) recipients of autografts (Table 
1. group VIII). have attained an insulin-free existence. this 
favorable outcome has not been witnessed in patients in 
other groups (Table 1). It is, however, interesting to note 
that one kidney + islet BM recipient (Table 1, group VI) 
was free of exogenous insulin for 1 week at 4 months 
post-Tx, but evolving hyperglycemia prompted the reinitia-
tion of insulin therapy. Notwithstanding that the recipients 
of delayed islet cell allografts are as yet insulin-dependent 
for the maintenance of euglycemia, it is nonetheless note-
worthy that many have exhibited normal levels of circulat-
ing Cpeptide in the 2 to 14 months of follow-up (Table 1, 
groups VI and VII); it still remains to be seen if any of these 
patients would ever achieve an insulin-free existence. Hav-
ing already established the utility of this technique for the 
treatment of diabetes, it is our contention that the advent of 
improved and long-term culture techniques and the initial 
success observed following delayed islet cell Tx may allow 
for wider clinical application of this procedure toward 
reversal of this disease. 
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